STOCK TITAN
  1. Home
  2. News
  3. BMEA

Biomea Fusion Inc - BMEA STOCK NEWS

Welcome to our dedicated news page for Biomea Fusion (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biomea Fusion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biomea Fusion's position in the market.

News
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) presented 26-week follow-up data from the COVALENT-111 study for BMF-219, an investigational covalent menin inhibitor for type 2 diabetes. The data showed improved glycemic control, increased insulin production, and expansion of beta cells in responders, with no severe adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.38%
Tags
clinical trial
-
News
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) announced the presentation of new preclinical and clinical data for BMF-219, an investigational menin inhibitor aiming to regenerate insulin-producing beta cells to cure diabetes. The data showed a sustained HbA1C reduction of ≥0.5% and ≥1.0% in 40% and 20% of patients, respectively, 22 weeks after the last dose. BMF-219 was generally well tolerated, displaying glucose-controlled beta cell proliferation in a preclinical ex-vivo human islet model. Biomea will also host a symposium at the 21st WCIRDC, presenting additional data on BMF-219's potential as a disease-modifying agent in type 2 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.54%
Tags
conferences clinical trial
-
News
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) has received clearance from Health Canada to initiate COVALENT-112, a Phase II clinical trial of BMF-219, a novel investigational covalent menin inhibitor, in adults living with type 1 diabetes. The trial will examine the safety, efficacy, and durability of BMF-219 at two oral dose levels, 100 mg and 200 mg, for 12 weeks of treatment followed by a 40-week off-treatment period. The trial will also include an open label portion, enrolling participants in the US and Canada with T1D up to 15 years since diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
clinical trial
News
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
Rhea-AI Summary
Biomea Fusion, Inc. (BMEA) announces the acceptance of three abstracts presenting new clinical data from the ongoing escalation portion of its COVALENT-111 trial, evaluating BMF-219 as a potential treatment for people with type 2 diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The new clinical data from all dosing cohorts initiated to date from the escalation portion of COVALENT-111 will be featured during a Poster Discussion Presentation and two Poster Viewing Presentations at ATTD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
none
-
News
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that its investigational novel covalent menin inhibitor, BMF-219, will be presented at the 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) meeting. The company will share topline data results of the escalation portion of COVALENT-111, a Phase I/II study designed to regenerate insulin-producing beta cells to cure diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
News
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) announced the acceptance of abstract showing long-term 26 weeks follow-up data of the first 20 patients from the first two dosing cohorts of COVALENT-111 for the 2023 Poster Session of the 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease. The company also revealed that topline data for the escalation portion of COVALENT-111 will be presented prior to year-end, including multiple BMF-219 dosing cohorts. The announcement includes the company's dedication to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
conferences clinical trial
News
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
Rhea-AI Summary
Biomea Fusion, Inc. announced that abstracts related to its investigational drugs, BMF-219 and BMF-500, have been accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting. BMF-219 is a covalent menin inhibitor being evaluated in multiple liquid and solid tumors, while BMF-500 is a covalent FLT3 inhibitor being studied in acute leukemias. The company reported positive preliminary Phase 1 data from the COVALENT-101 trial of BMF-219, showing two complete responses in acute myeloid leukemia patients with menin-dependent mutations. The clinical trials for both drugs are ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
none
-
News
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
Rhea-AI Summary
Biomea Fusion, Inc. reported positive results from its ongoing Phase II study in type 2 diabetes, with 84% of patients showing a reduction in HbA1c after 4 weeks of dosing. The expansion portion of the study is now enrolling participants. The company also received clearance for a Phase II clinical trial of BMF-219 in type 1 diabetes. In addition, Biomea dosed the first patient with BMF-500, its novel oral covalent inhibitor of FLT3, in relapsed/refractory AML. The company reported initial data from a Phase I trial of BMF-219 in relapsed/refractory AML, showing 2 complete responses out of 5 patients. Biomea also announced the appointment of a new Chief Medical Officer and had a cash position of $199.5 million at the end of Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.59%
Tags
earnings
-
News
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
Rhea-AI Summary
Biomea Fusion announces the initiation of Phase I trial for BMF-500, a covalent FLT3 inhibitor, in adult patients with relapsed or refractory acute leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
clinical trial
News
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
Rhea-AI Summary
Biomea Fusion receives FDA clearance for Phase II clinical trial of BMF-219 in adults with type 1 diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
clinical trial
Stock BMEA logo
Biomea Fusion Inc

Nasdaq:BMEA

BMEA Rankings

#3173 Ranked by Market Cap
#2016 Ranked by Stock Gains
N/A Ranked by Dividends

BMEA Stock Data

428.88M
19.38M
25.18%
87.06%
36.88%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Redwood City

About BMEA

biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro